These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 28460441)

  • 1. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies.
    Arora J; Sauer SJ; Tarpley M; Vermeulen P; Rypens C; Van Laere S; Williams KP; Devi GR; Dewhirst MW
    Oncotarget; 2017 Apr; 8(16):25848-25863. PubMed ID: 28460441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.
    Allensworth JL; Evans MK; Bertucci F; Aldrich AJ; Festa RA; Finetti P; Ueno NT; Safi R; McDonnell DP; Thiele DJ; Van Laere S; Devi GR
    Mol Oncol; 2015 Jun; 9(6):1155-68. PubMed ID: 25769405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.
    Evans MK; Brown MC; Geradts J; Bao X; Robinson TJ; Jolly MK; Vermeulen PB; Palmer GM; Gromeier M; Levine H; Morse MA; Van Laere SJ; Devi GR
    Cancer Res; 2018 Apr; 78(7):1726-1738. PubMed ID: 29351901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity.
    Evans MK; Sauer SJ; Nath S; Robinson TJ; Morse MA; Devi GR
    Cell Death Dis; 2016 Jan; 7(1):e2073. PubMed ID: 26821068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells.
    Allensworth JL; Aird KM; Aldrich AJ; Batinic-Haberle I; Devi GR
    Mol Cancer Ther; 2012 Jul; 11(7):1518-27. PubMed ID: 22508521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photothermal ablation of inflammatory breast cancer tumor emboli using plasmonic gold nanostars.
    Crawford BM; Shammas RL; Fales AM; Brown DA; Hollenbeck ST; Vo-Dinh T; Devi GR
    Int J Nanomedicine; 2017; 12():6259-6272. PubMed ID: 28894365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
    Robertson FM; Chu K; Boley KM; Ye Z; Liu H; Wright MC; Moraes R; Zhang X; Green TL; Barsky SH; Heise C; Cristofanilli M
    J Exp Ther Oncol; 2013; 10(3):219-33. PubMed ID: 24416998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).
    Joglekar-Javadekar M; Van Laere S; Bourne M; Moalwi M; Finetti P; Vermeulen PB; Birnbaum D; Dirix LY; Ueno N; Carter M; Rains J; Ramachandran A; Bertucci F; van Golen KL
    Neoplasia; 2017 Jul; 19(7):564-573. PubMed ID: 28609680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geometric tumor embolic budding characterizes inflammatory breast cancer.
    Modi AP; Nguyen JPT; Wang J; Ahn JS; Libling WA; Klein JM; Mazumder P; Barsky SH
    Breast Cancer Res Treat; 2023 Feb; 197(3):461-478. PubMed ID: 36473978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling and characterization of inflammatory breast cancer emboli grown in vitro.
    Lehman HL; Dashner EJ; Lucey M; Vermeulen P; Dirix L; Van Laere S; van Golen KL
    Int J Cancer; 2013 May; 132(10):2283-94. PubMed ID: 23129218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.
    Sauer SJ; Tarpley M; Shah I; Save AV; Lyerly HK; Patierno SR; Williams KP; Devi GR
    Carcinogenesis; 2017 Mar; 38(3):252-260. PubMed ID: 28426875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
    Ogony J; Choi HJ; Lui A; Cristofanilli M; Lewis-Wambi J
    Breast Cancer Res; 2016 Feb; 18(1):25. PubMed ID: 26897526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
    PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
    Salem I; Alsalahi M; Chervoneva I; Aburto LD; Addya S; Ott GR; Ruggeri BA; Cristofanilli M; Fernandez SV
    Breast Cancer Res; 2016 Mar; 18(1):37. PubMed ID: 27009091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
    Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M
    J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
    Aird KM; Ghanayem RB; Peplinski S; Lyerly HK; Devi GR
    Mol Cancer Ther; 2010 May; 9(5):1432-42. PubMed ID: 20406946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration.
    Buchheit CL; Angarola BL; Steiner A; Weigel KJ; Schafer ZT
    Cell Death Differ; 2015 Aug; 22(8):1275-86. PubMed ID: 25526094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
    Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
    Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.